Free Live Daily Updates: AMC Short Interest Today + More.
Community, I’m going to be updating this list of momentum stock and their short interest and utilization daily (AMC short interest, BBIG, MULN, BIOR, GME, APE, and many others).
Be sure to bookmark this page for daily AMC short interest updates and more.
Other metrics being updated daily will include the cost to borrow, shares on loan, + short squeeze scores.
If there are other heavily shorted stocks you’d like me to update daily, please leave a comment below and I’ll be sure to look into them before adding them to the list!
– Frank Nez
What has investing in the stock market taught you?
Stock Market 2023: Top stocks outperforming the SPY.
AMC Entertainment (NYSE:AMC) stock continues to be one of the biggest ‘meme stocks’ even after its massive debut in 2021 when shares rose from $2.50 to $72 later that year.
The stock, at the publication of this article, is trading at $6.08, the same share price it was two years ago before gaining serious traction.
AMC Entertainment continues to improve its fundamentals and remains the #1 leader in the movie theatre industry.
While online streaming has grown to become quite popular, especially during the pandemic, experts are beginning to weigh in on AMC’s side in 2023.
CNBC stated, “Netflix has backtracked on its previous policies, including by introducing an ad-supported subscription option, leading many to wonder whether the company should rethink its resistance to the traditional Hollywood movie release model as it looks for new ways to grow revenue.“
Even Amazon associates who asked not to be identified, per Bloomberg News, are stating the company plans to invest $1 billion per year in the movie theatre industry.
The world’s largest online retailer aims to make between 12 and 15 movies annually that will get a theatrical release.
“While a $1 billion annual investment for film development is on the lower end of what major Hollywood studios spend each year, it’s a positive sign for the movie theater business, which has struggled in the wake of the pandemic”, said CNBC.
Peloton Interactive, Inc. (NASDAQ:PTON) is an American exercise equipment and media company based in New York City.
The company’s products are stationary bicycles, treadmills, indoor rowers equipped with Internet-connected touch screens that stream live and on-demand fitness classes through a subscription service.
Company shares are up +109.11% year-to-date.
Peloton recently brought Leslie Berland, Twitter’s former marketing head, as its next chief marketing officer, per Bloomberg news reports.
She previously helped lead American Express for 10 years.
Peloton is trying to shift the tides after a rough 2022, when its stock dropped more than 75%.
The company in November posted wider losses than analysts expected for its first fiscal quarter.
Berland said in an announcement that she is “thrilled” to join the company at this “unique moment in its transformation journey.”
Stock Market 2023: Top stocks outperforming the SPY.
Tesla Inc. (NASDAQ:TSLA) had one of its worst years yet in 2022.
However, the company stock is outperforming the market today already gaining +74.16% in gains this year-to-date.
Tesla CEO Elon Musk sold 22 million shares of the company last year cashing in approximately $3.6 billion earlier in December according to this SEC filing.
After the massive selloff, Elon said during a Twitter space call that he will not sell any Tesla shares for about two years.
Musk said he sees a ‘serious’ recession in 2023 and is preparing for a worst-case scenario.
And although experts are saying a recession is likely to strike the U.S. economy during the first quarter of 2023, the company stock seems to be performing quite well today.
Shares of Hycroft Mining (NASDAQ:HYMC) rose 25% earlier this year when the company announced it had discovered more gold and silver than it had anticipated.
Majority of the company is owned by AMC Entertainment.
BIOR stock is up more than +71% this year-to-date but surged as much as +182% during the first trading week of January.
Formerly known as ‘Progenity’ (PROG), Biora Therapeutics stock is currently trading at $4.12.
The company may be heavily shorted, but there’s big opportunity for retail investors if the company’s clinical trials go well.
And so far, the company seems to be on track.
A big announcement such as the approval of their therapeutics program could trigger short sellers to run for the hills, initiating a short squeeze in Biora Therapeutics.
Will BIOR stock go up to its hundreds of dollars per share IPO levels again?
Here’s the latest BIOR stock news.
BIOR Stock News Today
BIOR Stock Short Interest + news today.
Biora Therapeutics is on track to move into clinic with its lead targeted therapeutics program.
For Biora’s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the company remains on track for an IND filing for its PGN-600 program followed by clinical trial initiation.
During Q4 2022, Biora continued its engagement with the FDA with a pre-IND supplemental Type C filing requesting agency feedback on its proposed PGN-600 clinical development plans, including the company’s proposed approach to toxicity studies and other aspects of its clinical plan.
“The recent Type C response from the FDA further strengthens our confidence in our plans to enter the clinic during the first half of 2023 with IND filing followed by trial initiation in Q2, and data readouts anticipated in Q3,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
For Biora’s Systemic Therapeutics program, the company has been transitioning from early concept to a clinical-ready device.
With several of the key device upgrades implemented, the company expects to report data from preclinical studies on its next-generation device during Q1 and Q2 of 2023.
If clinical trials prove to be a success, Biora Therapeutics’ platform will be approved for use.
Biora Therapeutics is on track to move into clinic with its lead targeted therapeutics program.
For Biora’s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the company remains on track for an IND filing for its PGN-600 program followed by clinical trial initiation.
During Q4 2022, Biora continued its engagement with the FDA with a pre-IND supplemental Type C filing requesting agency feedback on its proposed PGN-600 clinical development plans, including the company’s proposed approach to toxicity studies and other aspects of its clinical plan.
“The recent Type C response from the FDA further strengthens our confidence in our plans to enter the clinic during the first half of 2023 with IND filing followed by trial initiation in Q2, and data readouts anticipated in Q3,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
Biora Therapeutics has previously shown the strong potential of its Targeted Therapeutics platform to help patients with ulcerative colitis (UC) through data demonstrating that:
For Biora’s Systemic Therapeutics program, the company has been transitioning from early concept to a clinical-ready device.
With several of the key device upgrades implemented, the company expects to report data from preclinical studies on its next-generation device during Q1 and Q2 of 2023.
This is big news for the company and for BIOR shareholders alike.
The latest PROG stock news could be the reason why we’ve been seeing bullish price action this year.
If clinical trials prove to be a success, Biora Therapeutics’ platform will be approved for use.
This could yield a massive payout for shareholders invested in the company this year, a PROG short squeeze.
